Cargando…
Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer
BACKGROUND: Sarcopenia is an age-related syndrome that may have negative impact on surgical outcomes and long-term survival of patients with gastric cancer. Serum creatinine/cystatin C (Cr/CysC) ratio has attracted attention as a surrogate marker for sarcopenia but has not been adequately studied in...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772102/ https://www.ncbi.nlm.nih.gov/pubmed/35045814 http://dx.doi.org/10.1186/s12876-022-02093-4 |
_version_ | 1784635771703001088 |
---|---|
author | Sun, Jing Yang, Hui Cai, Wentao Zheng, Jingwei Shen, Ningzhe Yang, Xinxin Pan, Bujian Zhang, Weiteng Chen, Xiaodong Shen, Xian |
author_facet | Sun, Jing Yang, Hui Cai, Wentao Zheng, Jingwei Shen, Ningzhe Yang, Xinxin Pan, Bujian Zhang, Weiteng Chen, Xiaodong Shen, Xian |
author_sort | Sun, Jing |
collection | PubMed |
description | BACKGROUND: Sarcopenia is an age-related syndrome that may have negative impact on surgical outcomes and long-term survival of patients with gastric cancer. Serum creatinine/cystatin C (Cr/CysC) ratio has attracted attention as a surrogate marker for sarcopenia but has not been adequately studied in patients with gastric cancer. The purpose of this study was to investigate the validity of serum Cr/CysC ratio as a predictor of sarcopenia, evaluate a statistical cut-off value, and assess the relationship between Cr/CysC ratio and prognosis of patients with gastric cancer. METHODS: We retrospectively studied 327 patients who underwent surgery for gastric cancer from June 2009 to October 2021. The skeletal muscle mass index was calculated using computed tomography (CT). We determined the relevance of serum Cr/CysC ratio as a surrogate maker for sarcopenia by comparing it with various biomarkers. The Concordance index (C-index) was calculted to measure whether the Cr/CysC ratio can prognosis of patients with gastric cancer. RESULTS: Serum Cr/CysC was significantly correlated with with Skeletal Muscle Index (SMI) (r = 0.221, p < 0.001) and Skeletal Muscle Area (SMA) (r = 0.258, p < 0.001). The area under the curve for sarcopenia was significantly larger for serum Cr/CysC ratio than for other biomarkers (Cr/CysC: 0.644, CysC: 0.535, Cr: 0.556). Patients in the high-Cr/CysC group have longer survival time than that in low-Cr/CysC group, defined by the cutoff value 0.67. The C-index of both Cr/CysC ratio and SMI with OS was 0.63. CONCLUSIONS: Serum Cr/CysC ratio can be used accurately, inexpensively, and easily to evaluate sarcopenia in male patients with gastric cancer. Our study shows that patients with Cr/CysC below 0.67 had possibility of sarcopenia and would be poor prognosis. |
format | Online Article Text |
id | pubmed-8772102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87721022022-01-20 Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer Sun, Jing Yang, Hui Cai, Wentao Zheng, Jingwei Shen, Ningzhe Yang, Xinxin Pan, Bujian Zhang, Weiteng Chen, Xiaodong Shen, Xian BMC Gastroenterol Research BACKGROUND: Sarcopenia is an age-related syndrome that may have negative impact on surgical outcomes and long-term survival of patients with gastric cancer. Serum creatinine/cystatin C (Cr/CysC) ratio has attracted attention as a surrogate marker for sarcopenia but has not been adequately studied in patients with gastric cancer. The purpose of this study was to investigate the validity of serum Cr/CysC ratio as a predictor of sarcopenia, evaluate a statistical cut-off value, and assess the relationship between Cr/CysC ratio and prognosis of patients with gastric cancer. METHODS: We retrospectively studied 327 patients who underwent surgery for gastric cancer from June 2009 to October 2021. The skeletal muscle mass index was calculated using computed tomography (CT). We determined the relevance of serum Cr/CysC ratio as a surrogate maker for sarcopenia by comparing it with various biomarkers. The Concordance index (C-index) was calculted to measure whether the Cr/CysC ratio can prognosis of patients with gastric cancer. RESULTS: Serum Cr/CysC was significantly correlated with with Skeletal Muscle Index (SMI) (r = 0.221, p < 0.001) and Skeletal Muscle Area (SMA) (r = 0.258, p < 0.001). The area under the curve for sarcopenia was significantly larger for serum Cr/CysC ratio than for other biomarkers (Cr/CysC: 0.644, CysC: 0.535, Cr: 0.556). Patients in the high-Cr/CysC group have longer survival time than that in low-Cr/CysC group, defined by the cutoff value 0.67. The C-index of both Cr/CysC ratio and SMI with OS was 0.63. CONCLUSIONS: Serum Cr/CysC ratio can be used accurately, inexpensively, and easily to evaluate sarcopenia in male patients with gastric cancer. Our study shows that patients with Cr/CysC below 0.67 had possibility of sarcopenia and would be poor prognosis. BioMed Central 2022-01-19 /pmc/articles/PMC8772102/ /pubmed/35045814 http://dx.doi.org/10.1186/s12876-022-02093-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sun, Jing Yang, Hui Cai, Wentao Zheng, Jingwei Shen, Ningzhe Yang, Xinxin Pan, Bujian Zhang, Weiteng Chen, Xiaodong Shen, Xian Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
title | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
title_full | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
title_fullStr | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
title_full_unstemmed | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
title_short | Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
title_sort | serum creatinine/cystatin c ratio as a surrogate marker for sarcopenia in patients with gastric cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772102/ https://www.ncbi.nlm.nih.gov/pubmed/35045814 http://dx.doi.org/10.1186/s12876-022-02093-4 |
work_keys_str_mv | AT sunjing serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT yanghui serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT caiwentao serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT zhengjingwei serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT shenningzhe serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT yangxinxin serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT panbujian serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT zhangweiteng serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT chenxiaodong serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer AT shenxian serumcreatininecystatincratioasasurrogatemarkerforsarcopeniainpatientswithgastriccancer |